Suppr超能文献

[地高辛、呋塞米和血管扩张剂治疗重度充血性心力衰竭的结果]

[Results of treatment for severe congestive heart failure with digoxin, furosemide and vasodilating agents].

作者信息

Markiewicz K, Cholewa M, Górski L, Gawor Z, Dryjański T, Kaczkowska-Marusik E, Bubiński R

机构信息

I Kliniki Chorób Wewnetrznych, Instytutu Medycyny Wewnetrznej WAM w Lodzi.

出版信息

Pol Arch Med Wewn. 1990 Aug;84(2):86-97.

PMID:2277787
Abstract

In 61 patients with class IV (NYHA) of chronic congestive cardiac failure treated for 2 weeks with digoxin (0.290 +/- 0.108 mg/d) and furosemide (13.0 +/- 4.1 mg/d), for 2 weeks with digoxin, furosemide and isosorbide dinitrate (44.5 +/- 9.8 mg/d) or nifedipine (42.0 +/- 12.2 mg/d), for 4 weeks with digoxin, furosemide, isosorbide or nifedipine and captopril (angiotensin converting enzyme inhibitor) (75.1 +/- 24.4 mg/d), and for the last 2 weeks with digoxin, furosemide, isosorbide or nifedipine without captopril, after each stage the clinical state, exercise tolerance and haemodynamic parameters determined echocardiographically were assessed. Ten weeks of treatment by this method caused regression of pulmonary congestion in 80%, oedema in 63.3% and hepatomegaly in 33.3% of the patients. Moreover, 60.7% of the patients returned to class III, 13.1% to class II, and 26.2% remained in class IV (NYHA). In the group treated with digoxin, furosemide, nifedipine with captopril (n = 30) a significant rise was observed of the value of the ejection fraction and cardiac index in relation to the treatment with digoxin and furosemide and the treatment with digoxin, furosemide, nifedipine (p less than 0.05). No drug improved significantly the tolerance of submaximal exercise. During the treatment with captopril no clinical improvement was achieved in 4 cases, and worsening occurred in 3 cases of severe cardiac failure (7 of 61 patients, 11.5%). The obtained results showed that vasodilating drugs are safe in congestive cardiac failure and in many cases of severe failure captopril contributed to rapid clinical and haemodynamic improvement.

摘要

对61例纽约心脏协会(NYHA)心功能IV级的慢性充血性心力衰竭患者进行治疗,治疗方案为:第1阶段,地高辛(0.290±0.108mg/d)和呋塞米(13.0±4.1mg/d)联合治疗2周;第2阶段,地高辛、呋塞米与硝酸异山梨酯(44.5±9.8mg/d)或硝苯地平(42.0±12.2mg/d)联合治疗2周;第3阶段,地高辛、呋塞米、硝酸异山梨酯或硝苯地平与卡托普利(血管紧张素转换酶抑制剂)(75.1±24.4mg/d)联合治疗4周;最后阶段,地高辛、呋塞米、硝酸异山梨酯或硝苯地平联合治疗2周,停用卡托普利。在每个治疗阶段结束后,评估患者的临床状态、运动耐量以及通过超声心动图测定的血流动力学参数。采用该方法治疗10周后,80%的患者肺淤血消退,63.3%的患者水肿消退,33.3%的患者肝肿大消退。此外,60.7%的患者心功能恢复至III级,13.1%恢复至II级,26.2%仍为IV级(NYHA)。在接受地高辛、呋塞米、硝苯地平联合卡托普利治疗的组(n = 30)中,与接受地高辛和呋塞米治疗以及地高辛、呋塞米、硝苯地平治疗相比,射血分数和心脏指数的值显著升高(p<0.05)。没有药物能显著改善次极量运动的耐受性。在使用卡托普利治疗期间,4例患者无临床改善,3例严重心力衰竭患者病情恶化(61例患者中的7例,11.5%)。所得结果表明,血管扩张药物在充血性心力衰竭中是安全的,在许多严重心力衰竭病例中,卡托普利有助于快速实现临床和血流动力学改善。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验